Tenosynovial Giant Cell Tumor research hub
4 indexed studies · 1 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra-articular AMB-05X Injections in Subjects with Tenosynovial Giant Cell Tumor
This study is testing a new medicine called AMB-05X for a condition called Tenosynovial Giant Cell Tumor (TGCT). It's looking at how safe and effective the medicine is, how well people tolerate it, and how it works in the body. Researchers want to see if it shrinks the tumor.
Netherlands - active not recruitingPHASE3
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
This study looks at a new drug, vimseltinib, for a condition called Tenosynovial Giant Cell Tumor (TGCT) when surgery isn't possible. It compares vimseltinib to a dummy drug for 24 weeks, then everyone gets the real drug. It aims to see how well it shrinks tumors.
United States · Australia · Canada - active not recruitingPHASE1, PHASE2
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
This study is testing a new drug, vimseltinib, for advanced cancers and a specific joint condition called Tenosynovial Giant Cell Tumor (TGCT). It aims to find the right dose and see how well it works.
United States · Australia · Canada - active not recruitingPHASE3
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
This study is testing a new medicine, Pimicotinib, for a rare joint condition called Tenosynovial Giant Cell Tumor (TGCT). It aims to see if the medicine works and is safe for patients with TGCT that cannot be removed by surgery.
United States · Canada · China